[The matrix metalloproteinase 9 (MMP-9) and TIMP-1 activities in patients with chronic and recurrent pancreatitis].
The aim of study was to estimate the role of metalloproteinases 9 and TIMP-1 in the pathogenesis of chronic recurrent pancreatitis.


METHODS
The 63 patients with chronic recurrent pancreatitis were investigated with estimation of serum levels of MMP-9, TIMP-1, TNO-alpha and IL-1beta.


RESULTS
In patients with chronic recurrent pancreatitis the increase synthesis of proinflammatory cytokines and metalloproteinase 9 was estimated with a strong correlation between TNO-alpha and MMP-9 (r = 0.87, p = 0.001), and IL-1beta and MMP-9 (r = 0.81, p = 0.001).


CONCLUSIONS
In aggravation mechanisms of chronic recurrent pancreatitis take part the increase synthesis of MMP-9 after TNOalpha and IL-1beta activation. Addition to therapy of pancreatitis the Mexidol helps to decrease MMP-9 level and to increase the synthesis of MMP-9 antagonist - TIMP-1.
Akhmedov
V A
VA
Budylgin
A V
AV
Dolgikh
V T
VT
D000328:Adult; D000975:Antioxidants / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D053583:Interleukin-1beta / Q000096:biosynthesis / Q000097:blood; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000096:biosynthesis* / Q000097:blood; D008875:Middle Aged; D050500:Pancreatitis, Chronic / Q000097:blood / Q000201:enzymology* / Q000517:prevention & control; D010847:Picolines / Q000008:administration & dosage / Q000627:therapeutic use*; D055502:Secondary Prevention; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000096:biosynthesis* / Q000097:blood; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis / Q000097:blood
D000975:Antioxidants; D053583:Interleukin-1beta; D010847:Picolines; D019715:Tissue Inhibitor of Metalloproteinase-1; D014409:Tumor Necrosis Factor-alpha; C070020:emoxypine succinate; D020780:Matrix Metalloproteinase 9